Microfluidic and Organotypic Tumor Slice Culture Drug Testing Platform for Individualized Cancer Therapy


A drug combination screening/testing platform for individualized cancer therapy.

Key Benefits

  • Rapid screening of effective drug combination.
  • Integrated tumor microenvironment.
  • Identifying personalized therapy for individual cancer patient.

Market Summary
Treatment of children’s brain cancers is challenging because of the limitations current in vitro testing platforms and their lack of an intact tumor environment. The invention described is a microfluidic device that integrates the culture of living brain tumor slices that can provide rapid and reliable prediction, in real-time, of the best possible drug combinations for the treatment of children’s brain tumors. The global microfluidic devices market size was $6.8 billion in 2017 and is expected to reach $13.9 billion by 2022 with a CAGR of 15.3% from 2017-2022 (BCC Research SMC036E).

Technical Summary
Current in vitro drug combination screening is ineffective because of its inability to replicate the brain tumor microenvironment. The microfluidic device developed by researchers at Emory integrates the culture of living tumor slices as to provide rapid and reliable real-time prediction of the best possible drug combinations for juvenile brain tumors. This device contains living brain tumor slices which provide an intact microenvironment. Furthermore, the device consists of a high-precision chemical gradient generator which enables reliable testing of selected drug combinations.

Developmental Stage
The assay is currently in the stage of optimization.



Contact Information

TTO Home Page: https://emoryott.technologypublisher.com

Name: Hyeon (Sean) Kim

Title: Licensing Associate

Email: hkim70@emory.edu

Phone: 404-727-7218